ArticleNature medicine2022
Germline variants associated with toxicity to immune checkpoint blockade.
Abstract read
In one paragraph
Article in Nature medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 2 pooled it
10.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 2 syntheses or guidelines pooled it, 100 citations in OpenAlex.
- Identification of conserved immune-related adverse event risk factors and clinical outcomes in a pan-immunotherapy data mart.Journal for immunotherapy of cancer · 2025Pooled it
- Pooled it
- Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.Nature medicine · 2024Trial
- Inhibitory receptor profiles for joint prediction of benefit and toxicity in immune checkpoint blockade.iScience · 2026Review
- Population-Scale Precision Safety in Oncology Reveals Clinical and Genetic Determinants of Systemic Therapy Toxicity.medRxiv : the preprint server for health sciences · 2026Article
- Effectiveness and safety of immunotherapy in advanced NSCLC with pericardial effusions: a global retrospective multicenter study.The oncologist · 2026Observational
- DPP9-mediated inflammasome repression protects against checkpoint inhibitor lung toxicity.bioRxiv : the preprint server for biology · 2026Article
- The seventh kidney cancer research summit: progress in accelerating cures.The oncologist · 2026Article
- The contribution of rare germline variants to the immune landscape of breast cancer.Genome medicine · 2026Article
- Host Determinants of Immune Checkpoint Inhibitor Efficacy: Immune, Genetic, Metabolic, and Lifestyle Factors.International journal of molecular sciences · 2026Review
- Checkpoint inhibitor-induced hematologic immune-related adverse events and their association with disease recurrence in hematolymphoid malignancies: a clinical perspective.Blood research · 2026Review
- Decoding immunotherapy response through computational modeling.Nature communications · 2026Review
- Article
- Article
- Association ofJournal of clinical medicine · 2026Article
- Emerging biomarkers of immune checkpoint inhibitor toxicity in triple-negative breast cancer: a mini-review.Frontiers in immunology · 2026Review
- Sintilimab-Induced Sequential Multi-System Severe Immune-Related Adverse Events in an Elderly Patient with Esophageal Squamous Cell Carcinoma: A Case Report and Literature Review.OncoTargets and therapy · 2026Article
- Immune and inflammatory radiogenomics of radiotherapy-induced normal-tissue toxicity: genetic susceptibility, mechanisms, risk prediction, and clinical translation.Frontiers in immunology · 2026Review
- Immune checkpoint inhibitor-related endocrinopathies: from immune crosstalk to predictive biomarkers and precision management.Frontiers in endocrinology · 2026Review
- The role of metabolites in the causal effect of immune cell phenotypes on immunotherapy toxicity risk.Discover oncology · 2025Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
35 authors at 8 institutions in 3 countries.
Stefan GrohaDivision of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sarah Abou AlaiwiLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7073-3432
Wenxin XuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-8450-2037
Vivek NaranbhaiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Amin H NassarLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-8084-9105
Ziad BakounyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-1906-5704
Talal El ZarifLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-4507-2396
Renee Maria SalibyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Guihong WanHarvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-1100-4018
Ahmad RajehDepartment of Dermatology, Massachusetts General Hospital, Boston, MA, USA.
Elio AdibLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Pier V NuzzoLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5618-8079
Andrew L SchmidtDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Chris LabakiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Biagio RicciutiLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Joao Victor AlessiDepartment of Internal Medicine and Medical Specialties, School of Medicine, University of Genoa, Genoa, Italy.
David A BraunLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sachet A ShuklaBroad Institute of Harvard & MIT, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-2445-3584
Tanya E KeenanBroad Institute of Harvard & MIT, Cambridge, MA, USA.
Eliezer Van AllenBroad Institute of Harvard & MIT, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-0201-4444
Mark M AwadDepartment of Internal Medicine and Medical Specialties, School of Medicine, University of Genoa, Genoa, Italy.
Michael ManosDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Osama RahmaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Leyre ZubiriMassachusetts General Hospital, Boston, MA, USA.
Alexandra-Chloe VillaniBroad Institute of Harvard & MIT, Cambridge, MA, USA.
Benjamin FairfaxDepartment of Oncology, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0001-7413-5002
Christian HammerGenentech, South San Francisco, CA, USA.
Zia KhanGenentech, South San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-7859-3489
Kerry ReynoldsHarvard Medical School, Boston, MA, USA.
Yevgeniy SemenovHarvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7387-3094
Deborah SchragDivision of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Kenneth L KehlDivision of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5339-9797
Matthew L Freedman *Broad Institute of Harvard & MIT, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-0151-1238
Toni K Choueiri *Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9201-3217
Alexander Gusev *Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. alexander_gusev@dfci.harvard.edu.ORCID http://orcid.org/0000-0002-7980-4620
Harvard University · USBroad Institute · USBrigham and Women's Hospital · USDana-Farber Cancer Institute · USMassachusetts General Hospital · USUniversity of Genoa · ITUniversity of Oxford · GBYale Cancer Center · US
Funding
VectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI JENNIFER W MACK · 1985 to 2026
$330.6MTreating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI David McDermott · 2003 to 2026
$53.4MPhysician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1M(PQ3) A functional genomic approach to identification and interpretation of germline-tumor genetic interactionsR01CA227237 · NCI · DANA-FARBER CANCER INST · PI GUSEV, ALEXANDER, ZAITLEN, NOAH A · 2018 to 2022
$3.5MCharacterizing non-coding somatic and germline variant interactions in ovarian cancerR01CA244569 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI GAYTHER, SIMON ANDREW, GUSEV, ALEXANDER · 2020 to 2024
$3.3MCommon biology underlying pleiotropic breast, prostate and ovarian cancer risk lociR01CA259058 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI MATTHEW L FREEDMAN, Simon Andrew Gayther · 2022 to 2026
$2.5MImmunogenomic analytical approaches for research and clinical applicationsR50CA211482 · NCI · DANA-FARBER CANCER INST · PI SHUKLA, SACHET ASHOK · 2016 to 2020
$1.3MPredictive modeling of cutaneous immune checkpoint inhibitor toxicitiesK23AR080791 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI Yevgeniy R Semenov · 2023 to 2026
$704kEfficient methods for identifying cryptic relatedness in millions of individualsR21HG010748 · NHGRI · DANA-FARBER CANCER INST · PI GUSEV, ALEXANDER · 2019 to 2020
$372kNCI NIH HHS L30 CA264747NCI NIH HHS P30 CA006516NCI NIH HHS P50 CA101942NCI NIH HHS R01 CA227237NCI NIH HHS R01 CA244569NCI NIH HHS R01 CA259058NCI NIH HHS R50 CA211482NCI NIH HHS T32 CA009172NHGRI NIH HHS R21 HG010748NIAMS NIH HHS K23 AR080791Wellcome Trust 201488/Z/16/Z
Abstract
Immune checkpoint inhibitors (ICIs) have yielded remarkable responses but often lead to immune-related adverse events (irAEs). Although germline causes for irAEs have been hypothesized, no individual variant associated with developing irAEs has been identified. We carried out a genome-wide association study of 1,751 patients on ICIs across 12 cancer types. We investigated two irAE phenotypes: (1) high-grade (3-5) and (2) all-grade events. We identified 3 genome-wide significant associations (P < 5 × 10
Indexed as
Genome-Wide Association StudyImmune Checkpoint InhibitorsCognitionGerm CellsInterleukin-7Retrospective StudiesImmune Checkpoint InhibitorsInterleukin-7
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.